Scholarlink

Background <p>Pleural mesothelioma (PM) remains a lethal but preventable disease whose burden is shifting toward low- and middle-income countries (LMICs) where asbestos use has persisted or has only recently been banned. This study describes the clinical characteristics, management patterns, and prognostic factors of PM in a contemporary Colombian cohort.</p> Methods <p>We conducted a retrospective cohort study of adults with histologically confirmed pleural mesothelioma diagnosed at a tertiary referral cancer center in Bogotá, Colombia, from January 1, 2011, to December 31, 2023. Overall survival (OS) was defined from the histologic diagnosis date to death from any cause; patients without a recorded death were censored at the last documented oncologic contact. Real-world progression-free survival (PFS) was defined from diagnosis to documented progression (radiologic or clinician-documented) or death, whichever occurred first; patients without progression or death were censored at last contact. Survival was estimated using Kaplan–Meier methods and modeled using Cox proportional hazards regression.</p> Results <p>The cohort included 106 patients (mean age, 63.2&#xa0;years; 73.6% male; 84.9% epithelioid histology). There were 105 deaths (1 OS censor). Median OS was 9.9&#xa0;months (95% CI, 7.1–14.1), with 12- and 24&#xa0;month OS of 46.2% and 12.3%. Real-world PFS included 105 events (1 PFS censor). Median PFS was 8.1&#xa0;months (95% CI, 6.2–9.4), with 12- and 24&#xa0;month PFS of 30.2% and 6.6%. In multivariable analyses focused on baseline prognostic factors, ECOG performance status 2–3 was associated with shorter OS and PFS.</p> Conclusions <p>In this contemporary Colombian cohort, OS and PFS were short, and baseline functional status was strongly associated with outcomes. Treatment-stratified survival patterns are reported descriptively and should not be interpreted as comparative effectiveness. These data add regional evidence for pleural mesothelioma prognosis in routine practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and prognostic factors in pleural mesothelioma: insights from a Latin American cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Ricardo Brugés,
  • Carlos Carvajal,
  • Marcela Núñez,
  • Alejandra Navarrete,
  • Rafael Parra-Medina

摘要

Background

Pleural mesothelioma (PM) remains a lethal but preventable disease whose burden is shifting toward low- and middle-income countries (LMICs) where asbestos use has persisted or has only recently been banned. This study describes the clinical characteristics, management patterns, and prognostic factors of PM in a contemporary Colombian cohort.

Methods

We conducted a retrospective cohort study of adults with histologically confirmed pleural mesothelioma diagnosed at a tertiary referral cancer center in Bogotá, Colombia, from January 1, 2011, to December 31, 2023. Overall survival (OS) was defined from the histologic diagnosis date to death from any cause; patients without a recorded death were censored at the last documented oncologic contact. Real-world progression-free survival (PFS) was defined from diagnosis to documented progression (radiologic or clinician-documented) or death, whichever occurred first; patients without progression or death were censored at last contact. Survival was estimated using Kaplan–Meier methods and modeled using Cox proportional hazards regression.

Results

The cohort included 106 patients (mean age, 63.2 years; 73.6% male; 84.9% epithelioid histology). There were 105 deaths (1 OS censor). Median OS was 9.9 months (95% CI, 7.1–14.1), with 12- and 24 month OS of 46.2% and 12.3%. Real-world PFS included 105 events (1 PFS censor). Median PFS was 8.1 months (95% CI, 6.2–9.4), with 12- and 24 month PFS of 30.2% and 6.6%. In multivariable analyses focused on baseline prognostic factors, ECOG performance status 2–3 was associated with shorter OS and PFS.

Conclusions

In this contemporary Colombian cohort, OS and PFS were short, and baseline functional status was strongly associated with outcomes. Treatment-stratified survival patterns are reported descriptively and should not be interpreted as comparative effectiveness. These data add regional evidence for pleural mesothelioma prognosis in routine practice.